Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in BRCA-Associated or Unselected Metastatic Breast Cancer
NCT01525589Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jun 2012
- Primary completion
- Oct 2018
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of lurbinectedin in breast cancer, sponsored by PharmaMar. Started Jun 2012; status: completed.
02
Drugs
lurbinectedin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01525589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01525589.